Nurix Therapeutics Inc. (NRIX) News
Filter NRIX News Items
NRIX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NRIX News Highlights
- For NRIX, its 30 day story count is now at 4.
- Over the past 10 days, the trend for NRIX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- AGE, DEC and NX are the most mentioned tickers in articles about NRIX.
Latest NRIX News From Around the Web
Below are the latest news stories about NURIX THERAPEUTICS INC that investors may wish to consider to help them evaluate NRIX as an investment opportunity.
CFO Houte Van Sells 10,906 Shares of Nurix Therapeutics IncOn December 19, 2023, Houte Van, the CFO of Nurix Therapeutics Inc (NASDAQ:NRIX), executed a sale of 10,906 shares in the company, according to a recent SEC Filing. |
Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Price Is Right But Growth Is Lacking After Shares Rocket 44%Those holding Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shares would be relieved that the share price has rebounded 44... |
Judith A. Reinsdorf and Katherine M. Sandstrom Named to Toll Brothers Board of DirectorsFORT WASHINGTON, Pa., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE: TOL) (TollBrothers.com), the nation’s leading builder of luxury homes, today announced that Judith A. Reinsdorf and Katherine M. Sandstrom have joined the Company’s Board of Directors. In addition, Carl B. Marbach, age 82, has informed the Company that he will not stand for re-election and will step down from the Board at its next annual meeting of stockholders in March 2024. Ms. Reinsdorf, age 59, most recently s |
Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual MeetingPositive preliminary efficacy data with a favorable safety profile support plans to develop NX-5948 broadly in chronic lymphocytic leukemia (CLL) Rapid durable complete responses in a heavily pretreated relapsed/refractory patient population support continued development of NX-2127 in non-Hodgkin lymphoma (NHL) Nurix will webcast a Key Opinion Leader (KOL) event at 8:30 p.m. PT today to review data presented at the ASH meeting from its BTK degrader portfolio SAN FRANCISCO, Dec. 11, 2023 (GLOBE N |
Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual MeetingSAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that it will host a live webcast to review clinical data from the Phase 1 clinical trials of its Bruton’s tyrosine kinase (BTK) degrader programs, NX-5945 and NX-2127, which are being evaluated in patients with relapsed or refracto |
Nurix Therapeutics to Participate in Upcoming Investor ConferencesSAN FRANCISCO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in the following conferences in November: Stifel Healthcare ConferenceFireside chat: Tuesday, November 14, 2023, from 4:45 – 5:15 p. |
Nurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual MeetingSAN FRANCISCO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that clinical data will be presented for its two BTK degrader programs, NX-5948 and NX-2127, in two posters at the 65th American Society of Hematology Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, CA. |
Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 TrialCurrently enrolled patients may continue receiving NX-2127SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on U.S. Phase 1 NX-2127-001 study evaluating NX-2127 in various B-cell malignancies. Scre |
Down -34.9% in 4 Weeks, Here's Why Nurix Therapeutics, Inc. (NRIX) Looks Ripe for a TurnaroundNurix Therapeutics, Inc. (NRIX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
Nurix Therapeutics Inc (NRIX) Reports Q3 Fiscal 2023 Financial ResultsStrategic collaboration with Seagen and strong financial position highlight the quarter |